3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
14
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
96
Inflammatory Breast Neoplasms
9
Carcinoma, Intraductal, Noninfiltrating
8
Breast Neoplasms, Male
6
Breast Carcinoma In Situ
6
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Neoplasms
3
Locally Advanced Breast Cancer
2
HER2-positive Breast Cancer
2
Colorectal Neoplasms
2
Breast Cancer Patients
2
Stress, Psychological
1
Postoperative Complications
1
Pathologic Complete Response
1
Neovascularization, Pathologic
1
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
1
Motor Activity
1
Margins of Excision
1
Inflammation
1
Infertility
1
High-Risk Cancer
1
Head and Neck Neoplasms
1
Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Lobular
1
Breast Cancer-specific Survival
1
Breast Cancer Metastatic
1
Breast Cancer Invasive
1
Interventions
pembrolizumab
19
Docetaxel
9
atezolizumab
8
Cetuximab
8
Nivolumab
7
cemiplimab
6
Ipilimumab
4
Immune Checkpoint Inhibitors
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
palbociclib
3
fludarabine
3
durvalumab
3
avelumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Fulvestrant
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
Bortezomib
3
Blood Specimen Collection
3
seribantumab
2
selpercatinib
2
pazopanib
2
motexafin gadolinium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Neoadjuvant Therapy
×
Breast
×
Clear all
NCT03323424
2020-01-30
IRAM
Institut de Cancérologie de la Loire
Phase 2
Withdrawn